


NEXT GENERATION SUPPLY CHAINS FOR CELL & GENE THERAPIES AND ATMPs

OPEN  
**X-CELLerator**  
COMMUNITY



DELIVERING THE POWER  
OF **T CELLS** TO  
CANCER PATIENTS

# Managing the Supply Chain of First-in-Human Phase 1 TCR Bispecific (TCER®) Clinical Trials: Lessons Learned and Best Practices

**May 25, 2023**

Juliane Edel

Sr. Manager, CMC Commercial Strategy and Global Patient Supply, Immatics

# Disclaimer



This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision.

**Forward-Looking Statements.** Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the IND filing for IMA204, IMA301, IMA401, the Company’s focus on partnerships to advance its strategy, projections of future cash on hand and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Company undertakes no duty to update these forward-looking statements.


**No Offer or Solicitation.** This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company’s own internal estimates and research. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. This meeting and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization.

# Agenda

- Who is Immatics?
- What is TCER®?
- How do we bring TCER® to the patient?
- What did we learn and what do we conclude as best practices?


# Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics



<sup>1</sup> Phase 1a: Dose escalation, Phase 1b: Dose expansion; <sup>2</sup> Opdivo® (nivolumab): programmed death-1 (PD-1) immune checkpoint inhibitor;

\* Immatics proprietary ACTallo® platform utilizing Editas' CRISPR gene editing technology

# Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics



<sup>1</sup> Phase 1a: Dose escalation, Phase 1b: Dose expansion; <sup>2</sup> Opdivo® (nivolumab): programmed death-1 (PD-1) immune checkpoint inhibitor;

\* Immatics proprietary ACTallo® platform utilizing Editas' CRISPR gene editing technology


# Agenda

- Who is Immatics?
- What is TCER®?
- How do we bring TCER® to the patient?
- What did we learn and what do we conclude as best practices?

# TCER® – Immatics' TCR Bispecifics

## Proprietary TCER® Format Consisting of Three Distinct Elements

### T cell engaging receptor (TCER®)






# Delivering the Power of T cells to Cancer Patients

## Technology Platforms Discovery of Targets and TCRs

**XPRESIDENT®**

**XCEPTOR®**




# Delivering the Power of T cells to Cancer Patients

**Technology Platforms**  
Discovery of Targets and TCRs

**Two Distinct Modalities**  
Adoptive Cell Therapy and TCR Bispecifics

**Clinical Trials**  
Cancer Immunotherapy




# Delivering the Power of T cells to Cancer Patients

**Technology Platforms**  
Discovery of Targets and TCRs

**Two Distinct Modalities**  
Adoptive Cell Therapy and TCR Bispecifics


**Clinical Trials**  
Cancer Immunotherapy



# Agenda


- Who is Immatics?
- What is TCER®?
- How do we bring TCER® to the patient?
- What did we learn and what do we conclude as best practices?

# Patient Journey for Treatment with TCER<sup>®</sup>



→ Efficient communication with all stakeholders is key to the Patient Journey

# TCER® Supply Chain Flow




# Patient Journey for Treatment with TCER®

## Phase 1 (Dose-escalation Phase)

- Number and type of clinical trial material varies over all Dose Levels (DL)
- Patients are allowed to move up within cleared DL
- Weekly infusions over ~1 year

- Repeated ad-hoc shipments
- High reliance on vendors
- Thorough IRT setup & management




# Agenda

- Who is Immatics?
- What is TCER®?
- How do we bring TCER® to the patient?
- What did we learn and what do we conclude as best practices?



# Key Parameters for a Seamless Patient Journey

- Robust Supply Chain Planning and Forecasting
- Efficient Logistics and Timely Delivery
- Flexibility, Adaptability, and Continuous Improvement
- Collaboration and Communication
- Prioritization of Patient-Centricity

A close-up photograph of a woman wearing safety glasses and a lab coat, looking intently at a computer monitor in a laboratory setting. The background is blurred, showing lab equipment and a computer screen with some text.

DELIVERING THE POWER  
OF **T CELLS** TO  
CANCER PATIENTS

# Thank you

[www.immatics.com](http://www.immatics.com)



NEXT GENERATION SUPPLY CHAINS FOR CELL & GENE THERAPIES AND ATMPs

OPEN  
**X-CELLerator**  
COMMUNITY